Recent 8-K filings for FDMT
Highest-materiality recent filing
4DMT reports Q3 net loss $56.9M, enters Otsuka partnership for 4D-150 APAC rights for $85M upfront
- Net loss $56.9M in Q3 2025 vs $43.8M in Q3 2024; R&D expenses $49.4M (up from $38.5M).
- Otsuka partnership: $85M upfront + $50M cost sharing; up to $336M milestones + royalties. 4DMT retains ex-APAC rights.
-
4DMT Q1 net loss $68.8M; cash $458M; 4D-150 Phase 3 enrollment complete
Cash $458M as of Mar 31, 2026, down from $514M; expected to fund ops into H2 2028.
-
4DMT appoints CFO Kristian Humer as Principal Accounting Officer
Appointment effective March 25, 2026; Humer succeeds Ashoo Gupta.
-
4DMT FY2025 net loss $140M; cash $514M; 4D-150 Phase 3 enrollment completed
Net loss of $140M in FY2025 versus $161M in FY2024; R&D expenses $196M (up from $141M).
-
4D Molecular Therapeutics exchanges 6.6M shares for pre-funded warrants with RA Capital and BVF
RA Capital exchanged 4,850,000 shares for a warrant to acquire 4,850,000 shares.
-
Fariborz Kamal resigned as President/COO effective Dec 31, 2025; transitions to part-time Chief Technical Advisor.
-
Target enrollment for 4FRONT-1 and 4FRONT-2 Phase 3 trials raised from 400 to 480 patients each.
-
4D Molecular Therapeutics appoints Kristian Humer as CFO effective Nov 17, 2025
Kristian Humer, formerly CFO at Foghorn Therapeutics and Viridian Therapeutics, joins as CFO and Principal Financial Officer.
-
4DMT reports Q3 net loss $56.9M, enters Otsuka partnership for 4D-150 APAC rights for $85M upfront
Net loss $56.9M in Q3 2025 vs $43.8M in Q3 2024; R&D expenses $49.4M (up from $38.5M).
-
Sold 8,385,809 shares at $10.51/share and 1,128,949 pre-funded warrants at $10.5099 each.
-
Preliminary cash, equivalents and marketable securities $372.2M as of Sept 30, 2025.
-
4D Molecular Therapeutics (FDMT) signs $85M upfront license deal with Otsuka for 4D-150 in APAC
Upfront cash payment of $85M from Otsuka; additional cost sharing of at least $50M over next three years.
-
4D Molecular Therapeutics appoints Ashoo Gupta as Principal Financial Officer
Ashoo Gupta appointed Principal Financial Officer and Principal Accounting Officer effective September 30, 2025.
-
4DMT Q2 net loss $54.7M; accelerates 4D-150 Phase 3 wet AMD data to H1 2027
Cash $417M (down from $505M Dec 2024); funds into 2028; workforce cut ~25% saves ~$15M/yr.
-
4D Molecular Therapeutics reduces workforce 25%, accelerates wet AMD data to H1 2027; CFO resigns
CFO Uneek Mehra resigns effective July 15; remains principal financial officer through September 2025 and Q2 filing.
-
4D Molecular Therapeutics annual meeting results: all four proposals approved
Stockholders elected Jacob Chacko, Susannah Gray, and Charles Theuer as Class II directors.
-
4DMT Q1 net loss $48M; initiates 4D-150 Phase 3 in wet AMD; cash runway to 2028
Net loss $48.0M vs $32.4M YoY; R&D expenses $40.7M (+46% YoY) due to Phase 3 startup.
-
4DMT reports FY2024 net loss of $160.9M; cash $505M; Phase 3 programs on track
Net loss of $160.9M in 2024 vs $100.8M in 2023; R&D expenses $141.3M (up 46% YoY).
-
4D Molecular reports positive 52-week Phase 2b data for wet AMD therapy 4D-150
Phase 2b (n=30): 83% reduction in supplemental aflibercept injections (0.97 mean vs 6.0 on-label); 57% injection-free over 52 weeks.
-
4D Molecular reports positive 32-week DME data; FDA aligns on single Phase 3; cash runway into 2028
Cash, equivalents, securities $506M as of Dec 31; cash runway extended to 2028.
-
RA Capital exchanges 535k FDMT shares for pre-funded warrant at $0.0001 strike
RA Capital Healthcare Fund exchanged 535,000 shares of common stock for a pre-funded warrant to purchase 535,000 shares at $0.0001 per share.
-
4DMT reports Q3 2024 net loss $43.8M, cash $551M; 4D-150 Phase 3 on track for Q1 2025
Net loss $43.8M (vs $10.3M Q3 2023); R&D expense $38.5M (vs $25.1M) on trial progression.
-
4D-150 shows up to 98% injection reduction in wet AMD; Phase 3 4FRONT expected Q1 2025
Phase 2b Broad (n=30): 89% annualized injection reduction, 80% with 0 or 1 injection, 70% injection-free at 52 weeks.
-
Cash and equivalents $578M as of June 30, 2024; expected to fund operations into H1 2027.
-
Interim data from Phase 1/2 PRISM trial (Dose Expansion, Phase 2 Dose Expansion, Phase 2 Population Expansion cohorts) expected at September 2024 medical conference.
-
Planned Phase 3 dose (3E10 vg/eye): 89% reduction in mean annualized injection rate; 77% injection-free at 24 weeks.
-
4D Molecular Therapeutics enters $250M ATM equity distribution agreement with Leerink Partners
Company enters Sales Agreement to sell up to $250M common stock via at-the-market offering through Leerink Partners.
-
David Kirn, M.D. elected as Class I director with 35,630,613 votes for, 7,849,441 withheld, and 1,574,659 broker non-votes.
-
4DMT Q1 2024 net loss $32.4M; advances 4D-150 toward Phase 3 for wet AMD
Net loss $32.4M in Q1 2024 vs $28.7M in Q1 2023.
-
4DMT reports FY2023 net loss $100.8M; positive 4D-150 wet AMD data, Phase 3 plan Q1 2025
Net loss $100.8M in 2023; cash $299M at Dec 2023; Feb 2024 offering $281M net; runway into H1 2027.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material